MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis

Filippo Santoro, Franca Podo, Francesco Sardanelli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose MRI screening has been shown to allow for an earlier diagnosis of breast cancer in asymptomatic women with proven or suspected mutations in breast cancer susceptibility genes. Major efforts are presently addressed to assess to which extent this improves high-risk women survival. Methods We here discuss the article by Gareth et al (Breast Cancer Res Treat 145(3):663–672, 2014). Results Gareth and colleagues compared MRI sensitivity and specificity and clinical characteristics of breast cancers detected in their study with those reported in six similar prospective cohort screening studies. We here extended this analysis to a total of nine published cohort studies, including the High Breast Cancer Risk Italian Study 1 (HIBCRIT-1) for which we considered the final results published in 2011, instead of those of our interim report (2007) utilized by Gareth et al. Our updated analysis shows that in a total of 392 diagnosed breast cancers, 77 % (95 % confidence interval [CI] 73–81 %) were invasive and 52 % (95 % CI 46–58 %) were invasive grade 3. Only 23 % (95 % CI 18–28 %) of MRI-detected invasive breast cancers had metastatic lymph nodal involvement and 45 % (95 % CI 39–51 %) had a size ≤10 mm. Discussion and Conclusions The capability of MRI to detect invasive breast cancers at early stages could at least partly explain the significantly higher 10-year survival estimated by Gareth et al for asymptomatic highrisk women screened using MRI in the period 1997–2013 (95 %) compared with unscreened high-risk women diagnosed for breast cancer after 1990 and identified as BRCA1/BRCA2 mutation carriers in the years following diagnosis (74 %). It appears however worth noting that the evolution of therapeutic protocols applied to high-risk patients after the discovery of BRCA mutations in 1995-1997 could also have contributed to the observed difference in the survival of these two groups. On the other hand, we agree with Gareth et al that larger datasets are needed to evaluate to which extent improvements in the cancer detection impact on disease-free and overall survival of MRI-screened compared with mammography-alone-screened high-risk women.

Original languageEnglish
Pages (from-to)685-687
Number of pages3
JournalBreast Cancer Research and Treatment
Volume147
Issue number3
DOIs
Publication statusPublished - Sep 24 2014

Fingerprint

Survival Analysis
Breast Neoplasms
Confidence Intervals
Mutation
Survival
Cohort Studies
Neoplasm Genes
Lymph
Mammography
Early Detection of Cancer
Disease-Free Survival
Sensitivity and Specificity

Keywords

  • BRCA1/2
  • Breast cancer screening
  • High-risk
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

MRI screening of women with hereditary predisposition to breast cancer : diagnostic performance and survival analysis. / Santoro, Filippo; Podo, Franca; Sardanelli, Francesco.

In: Breast Cancer Research and Treatment, Vol. 147, No. 3, 24.09.2014, p. 685-687.

Research output: Contribution to journalArticle

@article{a8c0b5c82c1646149209b076a598ebbc,
title = "MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis",
abstract = "Purpose MRI screening has been shown to allow for an earlier diagnosis of breast cancer in asymptomatic women with proven or suspected mutations in breast cancer susceptibility genes. Major efforts are presently addressed to assess to which extent this improves high-risk women survival. Methods We here discuss the article by Gareth et al (Breast Cancer Res Treat 145(3):663–672, 2014). Results Gareth and colleagues compared MRI sensitivity and specificity and clinical characteristics of breast cancers detected in their study with those reported in six similar prospective cohort screening studies. We here extended this analysis to a total of nine published cohort studies, including the High Breast Cancer Risk Italian Study 1 (HIBCRIT-1) for which we considered the final results published in 2011, instead of those of our interim report (2007) utilized by Gareth et al. Our updated analysis shows that in a total of 392 diagnosed breast cancers, 77 {\%} (95 {\%} confidence interval [CI] 73–81 {\%}) were invasive and 52 {\%} (95 {\%} CI 46–58 {\%}) were invasive grade 3. Only 23 {\%} (95 {\%} CI 18–28 {\%}) of MRI-detected invasive breast cancers had metastatic lymph nodal involvement and 45 {\%} (95 {\%} CI 39–51 {\%}) had a size ≤10 mm. Discussion and Conclusions The capability of MRI to detect invasive breast cancers at early stages could at least partly explain the significantly higher 10-year survival estimated by Gareth et al for asymptomatic highrisk women screened using MRI in the period 1997–2013 (95 {\%}) compared with unscreened high-risk women diagnosed for breast cancer after 1990 and identified as BRCA1/BRCA2 mutation carriers in the years following diagnosis (74 {\%}). It appears however worth noting that the evolution of therapeutic protocols applied to high-risk patients after the discovery of BRCA mutations in 1995-1997 could also have contributed to the observed difference in the survival of these two groups. On the other hand, we agree with Gareth et al that larger datasets are needed to evaluate to which extent improvements in the cancer detection impact on disease-free and overall survival of MRI-screened compared with mammography-alone-screened high-risk women.",
keywords = "BRCA1/2, Breast cancer screening, High-risk, Magnetic resonance imaging",
author = "Filippo Santoro and Franca Podo and Francesco Sardanelli",
year = "2014",
month = "9",
day = "24",
doi = "10.1007/s10549-014-3097-1",
language = "English",
volume = "147",
pages = "685--687",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - MRI screening of women with hereditary predisposition to breast cancer

T2 - diagnostic performance and survival analysis

AU - Santoro, Filippo

AU - Podo, Franca

AU - Sardanelli, Francesco

PY - 2014/9/24

Y1 - 2014/9/24

N2 - Purpose MRI screening has been shown to allow for an earlier diagnosis of breast cancer in asymptomatic women with proven or suspected mutations in breast cancer susceptibility genes. Major efforts are presently addressed to assess to which extent this improves high-risk women survival. Methods We here discuss the article by Gareth et al (Breast Cancer Res Treat 145(3):663–672, 2014). Results Gareth and colleagues compared MRI sensitivity and specificity and clinical characteristics of breast cancers detected in their study with those reported in six similar prospective cohort screening studies. We here extended this analysis to a total of nine published cohort studies, including the High Breast Cancer Risk Italian Study 1 (HIBCRIT-1) for which we considered the final results published in 2011, instead of those of our interim report (2007) utilized by Gareth et al. Our updated analysis shows that in a total of 392 diagnosed breast cancers, 77 % (95 % confidence interval [CI] 73–81 %) were invasive and 52 % (95 % CI 46–58 %) were invasive grade 3. Only 23 % (95 % CI 18–28 %) of MRI-detected invasive breast cancers had metastatic lymph nodal involvement and 45 % (95 % CI 39–51 %) had a size ≤10 mm. Discussion and Conclusions The capability of MRI to detect invasive breast cancers at early stages could at least partly explain the significantly higher 10-year survival estimated by Gareth et al for asymptomatic highrisk women screened using MRI in the period 1997–2013 (95 %) compared with unscreened high-risk women diagnosed for breast cancer after 1990 and identified as BRCA1/BRCA2 mutation carriers in the years following diagnosis (74 %). It appears however worth noting that the evolution of therapeutic protocols applied to high-risk patients after the discovery of BRCA mutations in 1995-1997 could also have contributed to the observed difference in the survival of these two groups. On the other hand, we agree with Gareth et al that larger datasets are needed to evaluate to which extent improvements in the cancer detection impact on disease-free and overall survival of MRI-screened compared with mammography-alone-screened high-risk women.

AB - Purpose MRI screening has been shown to allow for an earlier diagnosis of breast cancer in asymptomatic women with proven or suspected mutations in breast cancer susceptibility genes. Major efforts are presently addressed to assess to which extent this improves high-risk women survival. Methods We here discuss the article by Gareth et al (Breast Cancer Res Treat 145(3):663–672, 2014). Results Gareth and colleagues compared MRI sensitivity and specificity and clinical characteristics of breast cancers detected in their study with those reported in six similar prospective cohort screening studies. We here extended this analysis to a total of nine published cohort studies, including the High Breast Cancer Risk Italian Study 1 (HIBCRIT-1) for which we considered the final results published in 2011, instead of those of our interim report (2007) utilized by Gareth et al. Our updated analysis shows that in a total of 392 diagnosed breast cancers, 77 % (95 % confidence interval [CI] 73–81 %) were invasive and 52 % (95 % CI 46–58 %) were invasive grade 3. Only 23 % (95 % CI 18–28 %) of MRI-detected invasive breast cancers had metastatic lymph nodal involvement and 45 % (95 % CI 39–51 %) had a size ≤10 mm. Discussion and Conclusions The capability of MRI to detect invasive breast cancers at early stages could at least partly explain the significantly higher 10-year survival estimated by Gareth et al for asymptomatic highrisk women screened using MRI in the period 1997–2013 (95 %) compared with unscreened high-risk women diagnosed for breast cancer after 1990 and identified as BRCA1/BRCA2 mutation carriers in the years following diagnosis (74 %). It appears however worth noting that the evolution of therapeutic protocols applied to high-risk patients after the discovery of BRCA mutations in 1995-1997 could also have contributed to the observed difference in the survival of these two groups. On the other hand, we agree with Gareth et al that larger datasets are needed to evaluate to which extent improvements in the cancer detection impact on disease-free and overall survival of MRI-screened compared with mammography-alone-screened high-risk women.

KW - BRCA1/2

KW - Breast cancer screening

KW - High-risk

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=84918491315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918491315&partnerID=8YFLogxK

U2 - 10.1007/s10549-014-3097-1

DO - 10.1007/s10549-014-3097-1

M3 - Article

C2 - 25178515

AN - SCOPUS:84918491315

VL - 147

SP - 685

EP - 687

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -